IDENTIFYING EVIDENCE ON THE COST-EFFECTIVENESS OF TREATMENTS AND COSTS/RESOURCE USE AND QUALITY OF LIFE OF PATIENTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA: SYSTEMATIC REVIEWS

被引：0
|
作者：
Monga, N. [1 ]
Garside, J. [2 ]
Gurung, B. [3 ]
Quigley, J. M. [3 ]
O'Donovan, M. [3 ]
Padhiar, A. [3 ]
Parisi, M. [4 ]
Tapprich, C. [5 ]
Nastoupil, L. [6 ]
机构：
[1] Janssen Global Oncol, Toronto, ON, Canada
[2] Janssen, High Wycombe, Bucks, England
[3] ICON Hlth Econ & Epidemiol, Abingdon, Oxon, England
[4] Janssen Global Oncol, Raritan, NJ USA
[5] Janssen Pharmaceut, Neuss, Germany
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.892
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY66
引用
收藏
页码：A556 / A556
页数：1
相关论文
共 50 条
  • [31] Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness
    Pickett, Karen
    Loveman, Emma
    Kalita, Neelam
    Frampton, Geoff K.
    Jones, Jeremy
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2015, 19 (86) : 1 - +
  • [32] COST-EFFECTIVENESS ANALYSIS OF MAINTENANCE TREATMENT WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA RESPONDING TO FIRST LINE INDUCTION THERAPY IN PORTUGAL
    Pereira, C.
    Rubio Terres, C.
    Rubio Rodriguez, D.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A530 - A531
  • [33] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB MAINTENANCE TREATMENT OF FOLLICULAR LYMPHOMA IN PATIENTS RESPONDING TO FIRST-LINE INMUNOCHEMOTHERAPY INDUCTION
    Castro-gomez, A. J.
    Lopez-Guillermo, A.
    Rueda, A.
    Salar, A.
    Rubio-Terres, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A446 - A446
  • [34] Cost-Effectiveness of Obinutuzumab Plus Chemotherapy Versus Rituximab Biosimilars Plus Chemotherapy for Patients with Previously Untreated Follicular Lymphoma
    Veenstra, David L.
    Guzauskas, Gregory F.
    Spencer, Scott J.
    Felizzi, Federico
    Launonen, Aino
    Dawson, Keith
    Masaquel, Anthony
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S280 - S280
  • [35] COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN THE UK
    Ray, J. A.
    Carr, E.
    Geary, U.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A343 - A343
  • [36] COST-EFFECTIVENESS OF OBINUTUZUMAB PLUS BENDAMUSTINE AND FOLLOWED BY OBINUTUZUMAB MAINTENANCE THERAPY IN CHINESE PATIENTS WITH RELAPSE AND REFRACTORY FOLLICULAR LYMPHOMA
    Ma, J.
    Zhen, B.
    Xia, Y.
    Gong, Q.
    Li, Y.
    Chen, W.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S84 - S84
  • [37] Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view
    Thielen, Frederick W.
    Kersten, Marie-Jose
    Kuizenga, Pim
    Hoogendoorn, Mels
    Posthuma, Eduardus F. M.
    Stevens, Wendy B. C.
    Uyl-de Groot, Carin A.
    Blommestein, Hedwig M.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1411 - 1422
  • [38] COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH FOLLICULAR LYMPHOMA. PRELIMINARY RESULTS
    Sabater, E.
    Rueda, A.
    Salar, A.
    Lopez-Guillermo, A.
    Oyagueez, I.
    Collar, J. M.
    [J]. HAEMATOLOGICA, 2014, 99 : 487 - 488
  • [39] Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission
    Hayslip, John W.
    Simpson, Kit N.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (03): : 166 - 170
  • [40] Cost-effectiveness of rituximab maintenance treatment versus autologous stem cell transplantation (ASCT) in patients with relapsed follicular lymphoma (FL).
    Leppae, Sirpa
    Linna, Miika
    Nyman, Heidi
    Taimela, Eeva
    [J]. BLOOD, 2006, 108 (11) : 952A - 952A
12345